BWS
CRL icon

Buck Wealth Strategies’s Charles River Laboratories CRL Stock Holding History

Buck Wealth Strategies’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$454 Buy
+2
New +$356 ﹤0.01% 1013

Other funds holding CRL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.65B AUM 9.66% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
VBA
Van Berkom & Associates Montreal, Quebec, Canada $3.1B AUM 12.88% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Buck Wealth Strategies's CRL Position: Q2 2026 in Review

Buck Wealth Strategies opened a new position in Charles River Laboratories (CRL) in Q2 2026: 2 shares worth $454. The stake represents ﹤0.01% of the portfolio and ranks #1013 among its holdings.

284 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Buck Wealth Strategies held 2 shares of Charles River Laboratories worth $454 as of Q2 2026.
  • Charles River Laboratories was a new Buck Wealth Strategies position in Q2 2026.
  • Charles River Laboratories made up ﹤0.01% of Buck Wealth Strategies's portfolio in Q2 2026, its #1013 holding.
  • 284 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Buck Wealth Strategies's 13F filing for Q2 2026, filed 30 Jul 2026.